Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

ToeFX Light Therapy for Chronic Venous Leg Ulcers

13. november 2026 opdateret af: Dr. Ahmed Kayssi

Adjunctive ToeFX Photodynamic Therapy for Chronic Venous Leg Ulcers: A Single-Arm, Open-Label Pilot Feasibility Study

Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.

A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.

The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.

This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.

The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.

A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.

ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.

This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

20

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada, M4L 3Y3
        • East Toronto Vascular Clinic
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18 years or older
  • Able to attend weekly visits for up to 12 weeks
  • Chronic venous leg ulcer (CEAP C6) of the lower extremity
  • Ulcer duration of 4 weeks or more
  • Ulcer size between 1 cm² and 20 cm² at baseline
  • Receiving standard-of-care compression therapy, or eligible to initiate it
  • Able to provide informed consent and comply with study procedures

Exclusion Criteria:

  • Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
  • Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
  • Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
  • Severe ischemia (ABI below 0.5) or poorly controlled diabetes (HbA1c above 10%)
  • Heavy exudate requiring negative-pressure wound therapy
  • Known photosensitivity or allergy to methylene blue or light-based therapies
  • Immunosuppressive therapy, radiation or chemotherapy within the past 3 months, or active malignancy
  • Pregnancy or lactation
  • Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
  • Participation in another interventional study within 30 days of screening

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Enhedens gennemførlighed
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ToeFX Treatment

Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure

Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation

Andre navne:
  • ToeFX
  • ClearToe Serum

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Treatment adherence
Tidsramme: Baseline through Visit 12/ end of treatment (up to 12 weeks)

Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions

Baseline through Visit 12/ end of treatment (up to 12 weeks)
Safety: Adverse Events
Tidsramme: Baseline through Healing Confirmation Visit (up to 14 weeks)

Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs

Baseline through Healing Confirmation Visit (up to 14 weeks)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percent Change in Wound Area From Baseline
Tidsramme: Baseline, week 4, week 8, and week 12

Percent change in wound area (cm²) from baseline

Baseline, week 4, week 8, and week 12
Complete wound epithelialization
Tidsramme: 12 weeks

Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician

12 weeks
Time to complete wound healing
Tidsramme: 12 weeks

Time (days) from baseline to complete epithelialization

12 weeks
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
Tidsramme: Baseline to 12 weeks/ end of treatment

Change in wound bed characteristics measured using the BWAT

Baseline to 12 weeks/ end of treatment
Change in pain score
Tidsramme: Baseline to 12 weeks/ end of treatment

Change in pain score (0-10 Numeric Rating Scale)

Baseline to 12 weeks/ end of treatment
Change in health-related quality of life
Tidsramme: 12 weeks/ end of treatment

Change in EQ-5D-5L score

12 weeks/ end of treatment
Patient satisfaction
Tidsramme: 12 weeks/ end of treatment

Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire

12 weeks/ end of treatment
Clinician feasibility
Tidsramme: 14 weeks or earlier if wound healing

Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow

14 weeks or earlier if wound healing
Absolute Change in Wound Area From Baseline
Tidsramme: Baseline, week 4, week 8, and week 12

Absolute change in wound area (cm²) from baseline

Baseline, week 4, week 8, and week 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Ahmed Kayssi, MD MSc FRCSC, East Toronto Vascular Clinic

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

15. november 2026

Primær færdiggørelse (Anslået)

31. oktober 2027

Studieafslutning (Anslået)

31. oktober 2027

Datoer for studieregistrering

Først indsendt

13. november 2026

Først indsendt, der opfyldte QC-kriterier

13. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • PRO04244160_ToeFX

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .